drugset / Trial / NCT00791271
Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion
Phase 1
Terminated
17 enrolled
M.D. Anderson Cancer Center
Eisai Inc. · collabSchering-Plough · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of the first phase of this clinical research study is to find the highest tolerable dose of decitabine and peginterferon alfa-2b that can be given in combination to patients with melanoma. The safety of this drug combination will also be studied. The goals of the second phase are to learn if decitabine and peginterferon alfa-2b combined can help to control melanoma, and to find out which doses are more effective and/or better tolerated.
Timeline
- Start
- 2008-09-02
- Primary completion
- 2015-05
- Completion
- 2015-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Decitabine | Small molecule | 10 mg/m2 | Intravenous |
| Subject | Peginterferon alfa-2b | Protein / enzyme biologic | 3 ug/kg | Subcutaneous |